Management Team

Stefan Aigner, MD, CFA
Chief Executive Officer
Ray DiFalco
President

Michael Innaurato

Chief Commercial Officer
Kip Martin
Chief Financial Officer
Manish Shah, MS, RPh
Chief Scientific Officer
Matthew Iverson
Vice President Clinical Development
Eric Kinzler, PhD
Vice President Medical Affairs
Carmela Pantaleon
Executive Director Clinical Development
Joseph Zajac
Vice President Commercial Operations

 


Stefan Aigner, MD, CFA
Chief Executive Officer
Dr. Aigner is CEO of the Company and is also the CEO and a co-founder of Inspirion Delivery Sciences.  From 2006 to 2008, Dr. Aigner was Executive Vice President, Corporate and Business Development at Alpharma, Inc., a global specialty pharmaceutical company. Before joining Alpharma, Dr. Aigner was co-founder and Executive Vice President of Business Development and Medical Affairs for Reliant Pharmaceuticals, Inc., a pharmaceutical company that specializes in the development, commercialization and marketing of prescription therapeutic products. During his tenure at Reliant, Dr. Aigner led the company through multiple acquisitions and significant in-licensing transactions and was responsible for building the company’s cardiovascular portfolio through partnerships with leading U.S. and European companies. Prior to working at Reliant, he was a consultant with healthcare consulting firm The Wilkerson Group from 1996 to 1999. Dr. Aigner graduated summa cum laude with a degree in medicine from the University of Erlangen, Nuremberg, Germany.

Ray DiFalco
President
Mr. DiFalco is co-founder and President of Inspirion Delivery Sciences He has more than twenty-five years of pharmaceutical industry experience working for both generic and branded pharmaceutical companies. He has extensive experience in bulk and finished product formulation and manufacturing, with a focus on solid, semi-solid and liquid pharmaceutical dosage forms. His responsibilities have ranged from facility design to finished product manufacturing for global pharmaceutical companies including Merck, Par Pharmaceuticals, Pfizer and Lederle (American Home Products). Mr. DiFalco has extensive experience in product approval inspection and cGMP facility compliance, and an extensive engineering background in facility construction, equipment installation and facility/equipment and process validation. Mr. DiFalco has a B.S. in Chemical Engineering and B.S. in Business Administration Management from Manhattan College and New York University. He is an inventor/co-inventor of various patents.

Michael Innaurato
Chief Commercial Officer
Mr. Innaurato has been working with Inspirion since 2013 and has more than 27 years of Pharmaceutical experience. From 1990-2012, Mr. Innaurato was employed by Purdue Pharma and was provided increasing responsibilities in Sales, Sales Training, Sales Management, Marketing, and Licensing and Business Development positions, his last position was Head of Marketing, Forecasting, Analytics, Market Research, Marketing Operations, Creative Services and Marketing Education. Mr. Innaurato’s breadth and depth of knowledge in the pain category is extensive as he was the original Brand Manager who launched OxyContin (which remains the most successful extended release opioid launch with peak sales of $2.8B), built and led Purdue’s U.S. specialty/hospital sales force, assisted Purdue’s Associated Companies with the launch of OxyContin in all major global markets and led the in-licensing of 3 pain programs.  From 1987-1989 he was a sales representative with Astra-Zeneca. Academically, Mr. Innaurato is a Cum Laude graduate of LaSalle University with a Bachelor of Science degree in Finance and Management.

Kip Martin
Chief Financial Officer
Mr. Martin has over fifteen years of pharmaceutical industry experience, primarily focused in the areas of corporate finance and corporate development.  Prior to Inspirion, Mr. Martin was Vice President of Business Development at Columbia Laboratories, Inc., a publicly traded pharmaceutical development company, where he evaluated strategic corporate and product acquisitions.  Prior to Columbia, Mr. Martin was Director of Business Development at Alpharma, Inc., a publicly-trade specialty pharmaceutical company that developed and launched the first abuse deterrent opioid approved by the FDA.  Mr. Martin was a founding employee of Reliant Pharmaceuticals, where he served as Director of Business Development.  Mr. Martin has extensive experience in product and company valuations, forecasting, financial analysis and modeling, and the development of unique financial and tax structures to optimize overall value.  Prior to joining Reliant, Mr. Martin was a Consultant with The Wilkerson Group, a boutique healthcare consulting firm in New York.  Mr. Martin has an MBA in finance from the Yale School of Management and a BS degree in mechanical engineering from Case Western Reserve University

Manish Shah, MS, RPh
Chief Scientific Officer

Mr. Shah is co-founder and Chief Scientific Officer of Inspirion Delivery Sciences. He has more than twenty-five years of pharmaceutical research and development experience in the areas of formulation, validation, analytics, manufacturing and regulation of drugs and drug products. He has successfully developed and received US FDA approvals of more than thirty prescription products, including both immediate-release and extended-release formulations, as well as over a dozen OTC products. Prior to IDT, Mr. Shah has also served in various research and development positions with Circa Pharmaceuticals, a division of Watson Pharmaceuticals; Schein Pharmaceuticals; and Zenith Laboratories, Inc. Mr. Shah holds a B.S. in Pharmacy from Poona University and an M.S. in Industrial Pharmacy from Arnold & Marie Schwartz College of Pharmacy, New York. He is an inventor/co-inventor of various patents and has published numerous papers. He is a Registered Pharmacist in the State of New York and New Jersey.

Matthew Iverson
Vice President Clinical Development

Mr. Iverson is our Senior Vice President of Clinical Development and was responsible for overseeing the filings for MorphaBond and RoxyBond at Inspirion. Prior to joining Inspirion, Mr. Iverson with VP of operations at Lifetree Clinical Research, a contract research organization specializing in the assessment of abuse deterrent opioid. While at Lifetree, Mr. Iverson oversaw the completion of over a dozen human abuse liability (drug liking) studies for major pharmaceutical companies. Prior to joining Lifetree, Mr. Iverson was Director of Clinical Research at ZARS. He graduated Delta Omega with a masters of public health from the University of Utah.

Eric Kinzler, PhD
Vice President Medical Affairs

Dr Kinzler has been working with Inspirion since 2013 and brings a wealth of industry knowledge in new product development and commercialization in specialty pharma. Dr Kinzler has more than 15 years of experience in the industry ranging from medical marketing to medical education and pharmacovigilance to regulatory compliance. Most recently, Dr Kinzler oversaw the Medical Affairs group at Xanodyne Pharmaceuticals, a specialty pharmaceutical company focused on branded pain management and women’s health products, where he participated in several NDA filings, as well as pre-commercial planning and product launch activities. Dr Kinzler graduated Cum Laude from the University of Colorado at Boulder before earning his doctorate in Cellular and Molecular Biology from the University of Wisconsin – Madison.

Carmela Pantaleon
Executive Director Clinical Development

Ms. Pantaleon is Director of Clinical Development at Inspirion Delivery Sciences.  She has 15 years of pharmaceutical experience in small to mid-size companies running Global Phase I-IV studies, using internal resources and CROs.  Most recently Ms. Pantaleon was employed with The Medicines Company where she managed a global mega trial and implemented a Phase IIb study, working with global regulatory agencies.  Ms. Pantaleon was previously with Reliant Pharmaceuticals where she managed the clinical programs for ANDA and NDA submissions.  Ms. Pantaleon has a B.S. in Biology from the University of California, San Diego.

Joseph Zajac
Vice President Commercial Operations

Mr. Zajac is a pharmaceutical industry veteran with more than thirty years of experience in sales and marketing operations and business analytics. Mr. Zajac has expertise in building and managing sales force operations for newly launched products, especially with rapid deployment of sales forces and providing support, measurement, and optimization of sales force effectiveness. Mr. Zajac was previously Head of Commercial Operations at XenoPort, Inc. and Vice President of Sales Operations and Business Analytics at Reliant Pharmaceuticals, Inc. He has created and managed multiple sales forces totaling as many as 1,000 members. Mr. Zajac spent a number of years with Clark-Neill and IMS in various sales, marketing and management positions of increasing responsibility. Early in his career Mr. Zajac was a sales representative with William H. Rorer, Inc. and a hospital representative with Johnson & Johnson. Mr. Zajac holds a B.A. from Princeton University and an M.B.A. from Lehigh University.